Mark H. Mirochnick, MD
Professor
Boston University School of Medicine
Dept of Pediatrics
Neonatology

MD, University of Vermont College of Medicine



Section Director
Boston University School of Medicine
Pediatrics
Neonatology

Active Staff Privileges
Boston Medical Center
Pediatrics




A 48 Week, Phase II, Open-Label, Multi-Cohort, Multicenter Study to Evaluate the Safety , Tolerability, Pharmacokinetics, and Antiviral Activity of GW433908/Ritonavir QD when Administered to HIV-1 Infected, Antiretrovitral Naive and Experienced, Pediatric
07/01/2002 - 06/30/2006 (PI)
GlaxoSmithKline, Inc.

Open-Label Multicenter Multiple Dose Phase III Study of the Population Pharmacokinetics of IV Synecid 7.5 mg/kg q8h in &5 Pediatric Patients
11/01/2001 - 10/31/2003 (PI)
Aventis Pharmaceuticals Inc

Investigation of CD11b Expression in Neonates Using New Laser Scanning Cytometer Technology
10/19/1999 - 09/30/2000 (PI)
CompuCyte Corporation


IMPAACT 2007 - Phase I Safety and Pharmacokeneticks of Marviorc in HIV 1 Exposed Infants at Risk …
07/01/2016 - 12/31/2018 (PI)
Johns Hopkins University Phivco UK II Ltd.

LDR 01: LOC-IMPAACT Leadership Group: Mirochnik
01/01/2014 - 11/30/2018 (PI)
Johns Hopkins University NIH-NIAID

Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention Trials
12/01/2012 - 11/30/2016 (PI)
Univ of California, San Francisco NIH-NIAID

IMPAACT: HIV Treatment SC VC
06/01/2012 - 12/31/2014 (PI)
Johns Hopkins University NIH-NIAID

IMPAACT: Network Executive Committee (NEC)
06/01/2012 - 12/31/2013 (PI)
Johns Hopkins University NIH-NIAID

IMPAACT Group Leadership
07/01/2006 - 06/30/2013 (PI)
Social & Scientific Systems Inc. NIH-NIAID

Pharmacokinetic Study of Praziquantel During Pregnancy
04/01/2009 - 03/31/2013 (PI)
Rhode Island Hospital NIH-NIAID

IMPAACT Leadership: International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)
06/01/2011 - 05/31/2012 (PI)
Social & Scientific Systems Inc. NIH-NIAID

Congenital Transmission of Lineages I and II of Trypanasoma Cruzi
09/08/2011 - 02/29/2012 (PI)
Tulane Univ Health Sciences Center NIH-NIA

Phase III Randomized Trial of the Safety and Efficency
11/01/2003 - 11/30/2010 (PI)
WESTAT NIH-NICHD

Showing 10 of 14 results. Show All Results


Yr Title Project-Sub Proj Pubs
2008 Safety Pharmacokinetics &Efficacy of Artemether &Lumefantrine in Pregnant Women 1R34AI076610-01
2007 ANTIRETROVIRAL DRUGS DURING PREGNANCY, SUBSTUDY OF PACTG P1025 2M01RR000533-39-8139 429
2007 PERINATAL CORE PROTOCOL FOR HIV INFECTED WOMEN (PACTG P1025, VERSION 20) 2M01RR000533-39-8144 429
2007 PHARMACOKINETICS OF ANTIRETROVIRAL DRUGS IN PREGNANT HIV INFECTED WOMEN 2M01RR000533-39-8160 429
2006 ANTIRETROVIRAL DRUGS DURING PREGNANCY, HIV INFECTED WOMEN (SUB OF PACTG P1025) 5M01RR000533-38-5584 429
2006 PERINATAL CORE PROTOCOL FOR HIV INFECTED WOMEN (PACTG P1025, VERSION 20) 5M01RR000533-38-5591 429
2006 Antiretroviral Pharmacology/Lactating Mother/Infants 5R21HD051470-02 1
2005 Antiretroviral Pharmacology/Lactating Mother/Infants 1R21HD051470-01 1
2005 ANTIRETROVIRAL DRUGS DURING PREGNANCY IN HIV POSITIVE FEMALES 5M01RR000533-37-5424 429
2005 PERINATAL CORE PROTOCOL IN HIV INFECTED WOMEN (PACTG P1025, VERSION 20) 5M01RR000533-37-444 429
Showing 10 of 22 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Mulligan N, Best BM, Wang J, Capparelli EV, Stek A, Barr E, Buschur SL, Acosta EP, Smith E, Chakhtoura N, Burchett S, Mirochnick M. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS. 2018 Mar 27; 32(6):729-737. PMID: 29369162.
     
  2. Schreiner CN, Ahlfors CE, Wong RJ, Stevenson DK, Clarke DF, Mirochnick M. In Vitro Study on the Effect of Maraviroc or Dolutegravir on Bilirubin to Albumin Binding. Pediatr Infect Dis J. 2018 Mar 15.View Related Profiles. PMID: 29561509.
     
  3. Adachi K, Xu J, Ank B, Watts DH, Camarca M, Mofenson LM, Pilotto JH, Joao E, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Machado DM, Ceriotto M, Morgado MG, Bryson YJ, Veloso VG, Grinsztejn B, Mirochnick M, Moye J, Nielsen-Saines K. Congenital CMV and HIV Perinatal Transmission. Pediatr Infect Dis J. 2018 Mar 09. PMID: 29528912.
     
  4. Eke AC, Chakhtoura N, Kashuba A, Best BM, Sykes C, Wang J, Stek AM, Smith E, Calabrese S, Capparelli EV, Mirochnick M. Rilpivirine Plasma and Cervico-Vaginal Concentrations in Women During Pregnancy and Postpartum. J Acquir Immune Defic Syndr. 2018 Mar 08. PMID: 29528944.
     
  5. Schalkwijk S, Ter Heine R, Colbers AC, Huitema ADR, Denti P, Dooley KE, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Mirochnick M, Burger DM. A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women. Clin Pharmacokinet. 2018 Mar 08. PMID: 29520730.
     
  6. Pinto JA, Capparelli EV, Warshaw M, Zimmer B, Cressey TR, Spector SA, Qin M, Smith B, Siberry GK, Mirochnick M. A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines. Pediatr Infect Dis J. 2018 Feb; 37(2):e29-e35. PMID: 29088027.
     
  7. Adachi K, Xu J, Yeganeh N, Camarca M, Morgado MG, Watts DH, Mofenson LM, Veloso VG, Pilotto JH, Joao E, Gray G, Theron G, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Ceriotto M, Machado DM, Bryson YJ, Grinsztejn B, Moye J, Klausner JD, Bristow CC, Dickover R, Mirochnick M, Nielsen-Saines K. Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission. PLoS One. 2018; 13(1):e0189851. PMID: 29304083.
     
  8. Friedman JF, Olveda RM, Mirochnick MH, Bustinduy AL, Elliott AM. Praziquantel for the treatment of schistosomiasis during human pregnancy. Bull World Health Organ. 2018 Jan 01; 96(1):59-65. PMID: 29403101.
     
  9. Clarke DF, Penazzato M, Capparelli E, Cressey TR, Siberry G, Sugandhi N, Mirochnick M. Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations. Expert Rev Clin Pharmacol. 2018 Jan; 11(1):83-93.View Related Profiles. PMID: 29039686.
     
  10. Rimawi BH, Johnson E, Rajakumar A, Tao S, Jiang Y, Gillespie S, Schinazi RF, Mirochnick M, Badell ML, Chakraborty R. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy. Antimicrob Agents Chemother. 2017 Jun; 61(6). PMID: 28348149; DOI: 10.1128/AAC.02213-16;.
     
Showing 10 of 104 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 104 publications over 30 distinct years, with a maximum of 9 publications in 2011

YearPublications
19863
19881
19901
19911
19933
19943
19951
19962
19971
19983
19997
20004
20013
20023
20033
20041
20054
20063
20072
20086
20093
20103
20119
20125
20134
20147
20155
20162
20174
20187
Contact for Mentoring:


771 Albany St
Boston MA 02118
Google Map


Mirochnick's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department